Therapy News and Research

RSS

Semaglutide, omega-3s and diet shift epigenetic aging clocks in human studies

A systematic review identified 41 human studies evaluating interventions targeting next-generation DNA methylation-based aging clocks. Pharmaceutical, lifestyle, supplement, clinical, and psychosocial interventions shifted some clock outputs, but these biomarkers remain investigational rather than proven clinical surrogates.

16 Jun 2026

New study uncovers how prostate cancer cells evade treatment

Cancer cells are remarkably good at adapting to stress. When treatments damage them, they often find new ways to survive, fueling drug resistance and disease progression.

16 Jun 2026

Salt-loaded nanoparticles help deliver fragile gene therapies into cells

Researchers at the University of Houston's College of Pharmacy have discovered an unexpected simple strategy to improve the performance of mRNA vaccines and gene therapeutics: adding salt.

16 Jun 2026

Real-time brain stimulation improves gait for Parkinson's patients

UC San Francisco researchers have developed a new form of deep brain stimulation (DBS) that adjusts in real time as a person walks, helping improve gait and reduce falls in people with Parkinson's disease.

16 Jun 2026

Novel embolization technique reduces pain from knee osteoarthritis

Embolization of abnormal blood vessels using rapidly resorbable gelatin-based microspheres is safe and provides significant, lasting pain relief and functional improvement for patients with osteoarthritis-related knee pain, according to a new study published today in Radiology, a journal of the Radiological Society of North America (RSNA).

16 Jun 2026

Doctors find unexpected regional differences in retinopathy of prematurity in Norway

It's a mystery. The eye disease known as retinopathy of prematurity (ROP) can make infants permanently blind if they are not treated. But there are big differences between how often Norwegian hospitals actually provide this treatment.

16 Jun 2026

New USC clinical trial explores psilocybin for mental health

Researchers at the Keck School of Medicine of USC, the Brain and Creativity Institute at the USC Dornsife College of Letters, Arts and Sciences, and the USC Norris Comprehensive Cancer Center have launched the University of Southern California's first study of psychedelic therapy.

16 Jun 2026

Clinical trial data shows preserved beta-cell function key to new paradigms in diabetes care

Critical Path Institute® (C-Path), through its Type 1 Diabetes Consortium, today reaffirmed its commitment to strengthening the regulatory-science and evidence infrastructure needed to enable the next phase of therapeutic innovation across multiple stages of type 1 diabetes (T1D).

16 Jun 2026

Lab-grown cell models reveal urate triggers vital renal water channels

Mayo Clinic researchers have identified a previously unrecognized way the kidneys regulate water balance - an advance that could lead to improved treatments for polycystic kidney disease (PKD) and other disorders. The study, led by Fouad Chebib, M.D., a nephrologist at Mayo Clinic, is published in the Journal of Clinical Investigation.

16 Jun 2026

Blocking a specific protein improves CAR T-cell therapy success in patients with blood cancers

University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.

15 Jun 2026

Reinforcing daily rhythms helps the brain recover after stroke

A new study from scientists at the University of Rochester Medicine suggests that reinforcing the body's natural daily rhythms to improve sleep could help the brain recover after a stroke, pointing to a potential new strategy to improve brain waste clearance and outcomes long after the initial injury.

15 Jun 2026

Tumor microenvironment drives drug resistance in lung cancer subtypes

A study by the University of Barcelona has discovered why the two main types of lung cancer — adenocarcinoma of the lung and squamous cell carcinoma — respond differently to anti-angiogenic therapy, that is, drugs that block the formation of new blood vessels that tumors need in order to grow.

15 Jun 2026

Dual-target CAR T therapy triggers broad immune response in brain cancer

Dual-target CAR T cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes and longer overall survival.

15 Jun 2026